ライフサイエンスコーパス: endothelin-1

1 ure to vasoconstrictors (50 mM KCl and 20 nM Endothelin-1).

2 creased production of vasoconstrictors (e.g. endothelin-1).

3 on of vascular endothelial growth factor and endothelin-1.

4 ression of the proalgesic/algogenic mediator endothelin-1.

5 zed mesenteric arteries pre-constricted with endothelin-1.

6 de (NO(.)) production and elevated levels of endothelin-1.

7 ypersensitivity to contractile stimulus with endothelin-1.

8 signaling and did not migrate in response to endothelin-1.

9 beta1, connective tissue growth factor, and endothelin-1.

10 cluding BNP (B-type natriuretic peptide) and endothelin-1.

11 tly greater contractility in response to big endothelin-1.

12 inducing the release of the vasoconstrictor, endothelin-1.

13 d peptides, including the vasoactive peptide endothelin-1.

14 (adjusted hazard ratio per log increment in endothelin-1, 1.57, 95% CI, 1.05-2.37; median follow-up,

15 on (adjusted odds ratio per log increment in endothelin-1, 1.66; 95% CI, 1.16-2.37).

16 (adjusted hazard ratio per log increment in endothelin-1, 1.69; 95% CI, 1.27-2.25; median follow-up,

17 ablished or to angiotensin II- (100 nmol/L), endothelin-1- (10 nmol/L), or phenylephrine- (10 micromo

18 ould be explained by an enhanced response to endothelin-1 (20% greater reduction in lumen diameter, P

19 pha) (+71% versus +1%), whereas it decreased endothelin-1 (-25% versus +5%) and the nitric oxide synt

20 her vehicle or IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)] at 2, 4, and 6h post occlusion.

21 the effect of IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)] on astrocytes, neurons, and vascular

22 IRL-1620 [Suc-[Glu9,Ala11,15]-Endothelin-1(8-12)], a highly selective ET(B) agonist, w

23 Endothelin-1, a marker of endothelial dysfunction, is a

24 Endothelin-1, a potent vasoconstrictor, plays an importa

25 is determined by venous endothelium-derived endothelin-1, acting through its specific receptor Ednra

26 Angiotensin II and endothelin-1 activated Camui, largely through an oxidati

27 dicate for the first time that intracellular endothelin-1 activates endolysosomal ET(B) receptors and

28 Endothelin-1 activates PKD via both rapid PKC-dependent

29 these proteins in DN, and demonstrated that endothelin-1 activates podocytes to release heparanase.

30 Endothelin-1 activates the phospholipase C pathway, lead

31 Endothelin-1 acts in an intracrine fashion on endolysoso

32 This is because endothelin-1 acts on Galpha(q/11) as well as Galpha(12/1

33 Endothelin-1 also stimulates adrenal aldosterone synthes

34 Endothelin-1, an extremely potent vasoconstrictor capabl

35 eased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory

36 We propose that downregulation of endothelin 1 and upregulation of vascular endothelial gr

37 ycoprotein to proteolipid protein 1 and both endothelin 1 and vascular endothelial growth factor.

38 of ARHGAP18 resulted in a failure to secrete endothelin-1 and a reduction in neutrophil transmigratio

39 r basal conditions and after the addition of endothelin-1 and abnormal spontaneous Ca(2+) release eve

40 (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB.

41 y PGP levels associate with both circulating endothelin-1 and acute rejection in cardiac transplant p

42 eraction with GRK2 is inversely regulated by endothelin-1 and CAV1 scaffolding domain after liver inj

43 imulates activated stellate cells to produce endothelin-1 and contract, via an ERK-dependent signalin

44 lacylcarnitines correlated with increases in endothelin-1 and creatinine/cystatin C, respectively.

45 be associated with higher levels of hepatic endothelin-1 and endocannabinoids, expression levels of

46 d afferent arteriole constrictor response to endothelin-1 and enhanced dilator response to acetylchol

47 Epithelial-derived endothelin-1 and fibroblast growth factor were also augm

48 -beta1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, hig

49 ined expression of their downstream targets, endothelin-1 and IFN-beta, respectively.

50 However, endothelin-1 and IL-6 increased, and IL-10 decreased, be

51 d increased contractility in the presence of endothelin-1 and larger basal mechanical tone in a uniqu

52 Levels of endothelin-1 and markers of fibrinolysis and inflammatio

53 mans, plasma CHGA correlated positively with endothelin-1 and negatively with GFR.

54 Plasma endothelin-1 and OPN concentrations are positively corre

55 mbin and PDGF selectively activate PKD2, and endothelin-1 and PMA activate both PKD1 and PKD2.

56 Despite pathophysiological links between endothelin-1 and pulmonary vascular remodeling, to our k

57 lpha by the epidermal cells and induction of endothelin-1 and transforming growth factor-beta in fibr

58 Here, CHGA led to the release of endothelin-1 and Weibel-Palade body exocytosis in cultur

59 ious pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before

60 ddressing 1 abnormality (eg, upregulation of endothelin-1) and were not developed specifically for PA

61 nce the hepatic vasoconstrictive response to endothelin-1, and aggravate hepatic microcirculatory dys

62 activation, such as smooth muscle actin and Endothelin-1, and all of these genes play a key role in

63 on, an enhanced vasoconstrictive response to endothelin-1, and an increased IHR were found to be asso

64 Circulating natriuretic peptides, endothelin-1, and catecholamine levels were unchanged.

65 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin.

66 transforming growth factor beta1 (TGFbeta1), endothelin-1, and NAD(P)H oxidase 4 also occur in parall

67 and erythroid hyperplasia to increased PlGF, endothelin-1, and pulmonary hypertension in SCD, and sug

68 s were significantly associated with anemia, endothelin-1, and tricuspid regurgitant velocity; the la

69 artiles); no pulmonary hypertension and high endothelin-1; and no pulmonary hypertension and low endo

70 k involving transforming growth factor-beta, endothelin-1, angiotensin II, CCN2 (connective tissue gr

71 Phosphodiesterase-5 (PDE-5) inhibitors and endothelin-1 antagonists influence endothelial function

72 th simvastatin added to PDE-5 inhibitors and endothelin-1 antagonists showed transient improvement in

73 e previously showed that both heparanase and endothelin-1 are essential for the development of DN.

74 he resulting autocrine functional effects of endothelin-1 are likely to be important in the wound-hea

75 signaling in endothelial cells and identify endothelin-1 as an upstream input and Ras/MEK/ERK as a d

76 es of evidence have demonstrated the role of endothelin-1 as both a constrictor of uterine myometrial

77 tor-2, and the potent vasoconstrictive agent endothelin-1 as compared with control cells.

78 duced by AngII, and identify vasopressin and endothelin-1 as potential therapeutic targets to counter

79 and nitrite, 6-keto-prostaglandin F(1alpha), endothelin-1, asymmetrical dimethylarginine, tumor necro

80 This reinforces the results based on endothelin-1, because phenylephrine is thought to act ex

81 Endothelin-1 binds two receptor subtypes, endothelin A (

82 In injured SECs, endothelin-1 blocked CAV1 phosphorylation induced by CAV

83 y in systemic sclerosis after macitentan, an endothelin-1 blocker.

84 emokine Receptor 2 (CXCR2) and production of endothelin-1 both in vitro and in vivo.

85 ls of the endothelium-derived C-terminal-pro-endothelin-1 (both p < 0.02).

86 a) and the neuroendocrine regulatory peptide endothelin-1 by DH82 cells.

87 Also, whether endothelin-1 can predict future heart failure and mortal

88 o-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patient

89 procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-at

90 Plasma endothelin-1 decreased during heating in controls but no

91 nd GNAI3 are core signaling molecules of the endothelin-1-distal-less homeobox 5 and 6 (EDN1-DLX5/DLX

92 ane and accumulate in the nucleus, while the endothelin-1 does not cause nuclear GRK5 localization.

93 This evidence suggests that endothelin-1 drives development of glomerulosclerosis an

94 eir interactions with other signals, such as Endothelin 1 (Edn1) and Jagged/Notch, which pattern the

95 previous studies have shown roles for BMPs, Endothelin 1 (Edn1) and Jagged1b-Notch2 in DV patterning

96 orsal Jag1 expression but also by inhibiting endothelin 1 (Edn1) expression in the pharyngeal endoder

97 g1b expression throughout the dorsal domain, Endothelin 1 (Edn1) inhibits jag1b and hey1 expression i

98 perturbations demonstrates complex roles for Endothelin 1 (Edn1) signaling in the intermediate joint-

99 reminiscent of the phenotypes observed when Endothelin 1 (Edn1) signaling, a key regulator of cartil

100 emonstrate rs9349379 regulates expression of endothelin 1 (EDN1), a gene located 600 kb upstream of P

101 etermine the selective affinity of EDNRA for endothelin 1 (EDN1), its major physiological ligand, and

102 ular density) and the potent vasoconstrictor endothelin 1 (EDN1); we assayed the activity of angioten

103 d cardiovascular progenitors using WNT3A and endothelin-1 (EDN1) human recombinant proteins.

104 nduced glomerulosclerosis is associated with endothelin-1 (EDN1) release by podocytes, which mediates

105 n multiple signaling pathways, in particular Endothelin-1 (Edn1), Bone Morphogenetic Protein (BMP), a

106 Endothelin-1 (Edn1)-induced signaling through the endoth

107 (Ednra) expression and increased circulating endothelin-1 (Edn1).

108 a and recruitment of vasoconstrictors (e.g., endothelin-1; Edn1) leads to clearance of transplanted c

109 Stimulation of primary mouse podocytes with endothelin-1 elicited rapid calcium transients mediated

110 egulator of genes controlling vascular tone [endothelin-1, endothelin-1 receptor type A, and endothel

111 such as transforming growth factor beta1 and endothelin-1, enhance RBC NADPH oxidase activity and inc

112 Endothelin 1 (ET-1) evokes histamine-independent pruritu

113 des, of which 3 distinct isoforms exist, and endothelin 1 (ET-1) is the most abundant and the best-ch

114 Endothelin 1 (ET-1), mainly produced from vascular endot

115 mpaired vasodilator reactivity and increased endothelin 1 (ET-1)-mediated vasoconstriction, two abnor

116 In the first protocol, injection of endothelin 1 (ET-1, 1, 2 and 4 microg) into the left atr

117 Aldosterone and endothelin-1 (ET-1) act on collecting duct cells of the

118 l vector resulted in significantly increased endothelin-1 (ET-1) and a significantly decreased endoth

119 newborn arteries also expresses and releases endothelin-1 (ET-1) and initiates endothelium-dependent

120 s, correlate with increased plasma levels of endothelin-1 (ET-1) and other functional markers of PH i

121 creased levels of the potent vasoconstrictor endothelin-1 (ET-1) and PHT.

122 revealed marked increases in the content of endothelin-1 (ET-1) and transforming growth factor-beta

123 Endothelin-1 (ET-1) antagonists are a possibility becaus

124 Gene profiling identified inter alia endothelin-1 (ET-1) as one of the target genes of P2Y4 i

125 Here, we observed that endothelin-1 (ET-1) attenuates ENaC activity acutely by

126 Hepatic production and release of endothelin-1 (ET-1) binding to endothelin B (ETB) recept

127 Previous studies suggest that endothelin-1 (ET-1) contributes to the pathogenesis of E

128 e presence of PLCbeta3 but not TRPV1, and 3) endothelin-1 (ET-1) does not require either PLCbeta3 or

129 Endothelin-1 (ET-1) dose and time-dependently up-regulat

130 ivation of endothelin-A receptor (ET(A)R) by endothelin-1 (ET-1) drives epithelial-to-mesenchymal tra

131 (NGAL), kidney injury molecule-1 (KIM-1) and endothelin-1 (ET-1) during EVKP in a series of discarded

132 r induces the release of the vasoconstrictor endothelin-1 (ET-1) from pulmonary microvascular endothe

133 The vasoconstricting protein endothelin-1 (ET-1) has been implicated in this process,

134 Endothelial expression and the release of endothelin-1 (ET-1) in levels sufficient to initiate vas

135 Endothelin-1 (ET-1) induces matrix-associated gene expre

136 Endothelin-1 (ET-1) is a 21-amino acid vasoactive peptid

137 Endothelin-1 (ET-1) is a potent endothelial-derived vaso

138 Although endothelin-1 (ET-1) is a potent vasoconstrictor peptide

139 The vasoconstrictor peptide endothelin-1 (ET-1) is a transcriptional target of TGF-b

140 The present study demonstrates that endothelin-1 (ET-1) is an astrocyte-derived signal that

141 Elevated circulating endothelin-1 (ET-1) is associated with the disease.

142 Since endothelin-1 (ET-1) is implicated in blood pressure (BP)

143 termine whether vascular endothelial-derived endothelin-1 (ET-1) is important for skin Na(+) bufferin

144 ceptor mediating the vasodilatory effects of endothelin-1 (ET-1) is induced by OA-NO2 Inasmuch as ET-

145 tic brain injury or subarachnoid hemorrhage, endothelin-1 (ET-1) is induced resulting in cerebral vas

146 Endothelin-1 (ET-1) is involved in the pathogenesis of c

147 estigated whether the potent vasoconstrictor endothelin-1 (ET-1) is involved.

148 cells are a major source of TGFbeta and that endothelin-1 (ET-1) is one of the key components respons

149 Endothelin-1 (ET-1) is unique among a broad range of hyp

150 Increased endothelin-1 (ET-1) levels, disordered thiol protein sta

151 rum concentrations of the vasoactive protein endothelin-1 (ET-1) occur in the setting of systemic inf

152 The present study investigated the effect of endothelin-1 (ET-1) on cholinergic mechanisms of end-org

153 n endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting

154 h have demonstrated that the peptide hormone endothelin-1 (ET-1) plays multiple, complex roles in car

155 pig retinal arterioles under normal tone or endothelin-1 (ET-1) pre-contracted conditions and determ

156 Endothelin-1 (ET-1) promotes renal damage during cardiov

157 BQ-123 (0.4 mg/h) was used to block the endothelin-1 (ET-1) receptor A.

158 ls (termed TRPC1 channels) by stimulation of endothelin-1 (ET-1) receptor subtypes in freshly dispers

159 We show that endothelin-1 (ET-1) stimulates InsP(3)-induced Ca(2+) re

160 edominantly responsible for producing active endothelin-1 (ET-1), a mitogenic peptide implicated in t

161 Endothelin-1 (ET-1), a phospholipase C-coupled receptor

162 Endothelin-1 (ET-1), a potent vasoconstrictor, has been

163 ) correlated with increased plasma levels of endothelin-1 (ET-1), a potent vasoconstrictor, in sickle

164 rin directly stimulates the transcription of endothelin-1 (ET-1), a secreted proinvasive polypeptide

165 onse of human peripheral microvasculature to endothelin-1 (ET-1), examined the role of specific ET re

166 ral fold increases in the mRNA expression of endothelin-1 (ET-1), hypoxia-inducible factor-1alpha (HI

167 Vasoconstrictors, including endothelin-1 (ET-1), inhibit myocyte BK channels, leadin

168 ed an endogenous inhibitor of remyelination, Endothelin-1 (ET-1), which is highly expressed in reacti

169 NA (siRNA) in ventricular myocytes decreases endothelin-1 (ET-1)-dependent elevation of nuclear calci

170 tion of RhoA at Ser188, to the inhibition of endothelin-1 (ET-1)-induced activation of RhoA, and to t

171 ined nitric oxide (NO)-mediated dilation and endothelin-1 (ET-1)-induced constriction in retinal arte

172 dy state [Ca(2+)](i), and protection against endothelin-1 (ET-1)-induced steady state [Ca(2+)](i) inc

173 isoproterenol (ISO), phenylephrine (PE), and endothelin-1 (ET-1).

174 decreased the positive inotropic response to endothelin-1 (ET-1).

175 In EOC, the endothelin-1 (ET-1, EDN1)-endothelin A receptor (ETAR, E

176 eurohumoral stimuli that induce hypertrophy, endothelin-1 (ET1) and phenylephrine (PE), trigger compa

177 Endothelin-1 (ET1) synthesis is understood to promote ca

178 Endothelin-1 exerts its actions via activation of ET(A)

179 Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively, of the

180 pain behavior, epidermal tissue damage, and endothelin-1 expression.

181 ivation and angiotensin-induced increases in endothelin-1 expression.

182 ivation was required for fibronectin-induced endothelin-1 expression.

183 e sarcomere and activation of calcineurin by endothelin-1-facilitated interaction between FHL2 and ca

184 fibroblasts were treated with 20 and 100 nM endothelin-1 for 6 and 24 hours and then collected to as

185 In addition, CHGA triggered secretion of endothelin-1 from glomerular endothelial cells and TGF-b

186 en a modest ( approximately 35%) decrease in endothelin-1 gene (Edn1) expression is sufficient to cau

187 dney vasculature and normalized Tgf-beta and endothelin-1 gene expression in aged MWF rats.

188 array analysis showed increased Tgf-beta and endothelin-1 gene expression with age.

189 generated low-expressing and high-expressing endothelin-1 genes (L and H) and have bred mice with fou

190 ary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary h

191 Endothelin-1 has autocrine effects on stellate cells and

192 d mitogenic paracrine growth factors such as endothelin 1, hepatocyte growth factor, alpha-melanocyte

193 ubgroup with pulmonary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper qua

194 tions in plasma vasopressin, upregulation of endothelin-1 in cerebral resistance arterioles and activ

195 de (NO)/reactive oxygen species balance, and endothelin-1 in conduit artery endothelial dysfunction d

196 phy signaling triggered by angiotensin II or endothelin-1 in HEK293T cells as well as in neonatal and

197 expression of the pulmonary vasoconstrictor endothelin-1 in pulmonary endothelial cells.

198 the expression of contractile markers and of endothelin-1 in VSMCs.

199 In human pulmonary artery endothelial cells, endothelin-1 increased aldosterone levels via peroxisome

200 In vitro, treatment with endothelin-1 increased total beta-catenin and phospho-NF

201 Furthermore, intracellular endothelin-1 increases nitric oxide via an ET(B)-depende

202 s not known whether elevated serum levels of endothelin-1 indicate future risk of kidney disease in t

203 e complement anaphylatoxins C3a and C5a, and endothelin 1, induced human MCs rapidly to secrete small

204 In endothelial cells, the endothelin-1-induced Ca(2+) response is abolished upon e

205 However, endothelin-1-induced constriction was significantly enha

206 , ROCK activation mediates myogenic tone and endothelin-1-induced vasoconstriction.

207 Endothelin-1 induces lung fibroblast proliferation and c

208 e CKD by enhanced ADORA2B signaling-mediated endothelin-1 induction in a hypoxia-inducible factor-alp

209 Therapy with prostanoids, endothelin-1 inhibitors and phosphodiesterase-5 inhibito

210 We conclude that endothelin-1 is critical for maintaining normal contract

211 Endothelin-1 is elevated in women with polycystic ovary

212 Endothelin-1 is known to stimulate endothelial nitric ox

213 0.05), but not in vascular endothelial cell endothelin-1 knockout (VEET KO) mice (76.4 +/- 5.7 pg/mg

214 ular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538).

215 Phenotyping by pulmonary hypertension and endothelin-1 level showed mortality decreasing in order

216 Log-transformed plasma endothelin-1 level.

217 heart, vascular remodeling, and raised serum endothelin 1 levels.

218 ur knowledge, the association between plasma endothelin-1 levels and pulmonary hypertension has not b

219 ied African American individuals with plasma endothelin-1 levels and tricuspid regurgitation on echoc

220 In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all

221 en-binding activity, soluble E-selectin, and endothelin-1 levels by using ELISA and BRAHMS Kryptor te

222 Participants with baseline endothelin-1 levels in higher quartiles had a greater in

223 Mean (SD) endothelin-1 levels were 1.36 (0.64) pg/mL; 217 of 3223

224 In rats with PAH, elevated endothelin-1 levels were associated with elevated aldost

225 g for potential confounders, log-transformed endothelin-1 levels were associated with increased odds

226 Log-transformed endothelin-1 levels were associated with mortality (adju

227 Basal and angiotensin-stimulated big endothelin-1 levels were elevated in Tg(Prkcb)apoE-/- mi

228 terminal telopeptide of collagen type I, and endothelin-1 levels were higher in diabetic patients (p

229 Endothelin-1 levels were significantly increased 20 hr a

230 Elevated plasma endothelin-1 levels, especially associated with an eleva

231 lin-1; and no pulmonary hypertension and low endothelin-1 (log-rank chi2 = 77.16; P < .01 ).

232 er quartile); pulmonary hypertension and low endothelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonar

233 wth factor-b, interleukin-1b, interleukin-6, endothelin-1, matrix metalloproteinase-9, plasminogen ac

234 tion of the endothelin-A receptor (EDNRA) by endothelin-1 may play a role in the disease because the

235 expression of smooth muscle alpha-actin and endothelin-1-mediated autocrine stellate cell contractio

236 to histaminergic (histamine, compound 48/80, endothelin-1), not non-histaminergic (chloroquine) pruri

237 However, no direct pathogenic effect of endothelin-1 on podocytes has been shown in vivo and end

238 atory BP), arterial stiffness, nitric oxide, endothelin 1, or blood lipid profile.

239 th the concentration of the vasoconstrictor, endothelin 1 (P = 0.0005), and negatively with the conce

240 on in NO/reactive oxygen species balance and endothelin-1 pathway, to conduit artery endothelial dysf

241 hese results indicate that activation of the endothelin-1 pathways selectively in podocytes mediates

242 Endothelin-1 positively associated with all-cause mortal

243 Blocking endothelin-1 prevented these phenotypic changes.

244 We provide evidence that microinjected endothelin-1 produces a dose-dependent elevation in cyto

245 tes production of the potent vasoconstrictor endothelin-1, producing pulmonary hypertension.

246 , particularly of fibronectin, in regulating endothelin-1 production during liver injury.

247 ADORA2B activation that directly stimulates endothelin-1 production in a hypoxia-inducible factor-al

248 Consequently, endothelin-1 production increased, right ventricle press

249 sed to measure specific variables, including endothelin-1 production.

250 Endothelin-1 promotes mesangial cell proliferation and s

251 Endothelin-1 promotes vasculopathy in systemic sclerosis

252 l as in human disease, including the role of endothelin-1, pulmonary monocytes, and angiogenesis.

253 iewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial a

254 e found that tumor-derived ET-1 acts through endothelin-1 receptor A (ETAR) to enhance migration and

255 e with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism.

256 wn to improve Raynaud's Condition Score; the endothelin-1 receptor antagonist bosentan has now been s

257 Our data do not support the use of the dual endothelin-1 receptor antagonist, bosentan, in patients

258 Treatment with endothelin-1 receptor antagonists could theoretically im

259 Our findings suggest that endothelin-1 receptor antagonists, already licensed for

260 , whereas pretreatment of rats with the dual endothelin-1 receptor blocker, bosentan, improved cell e

261 ion was associated with increased glomerular endothelin-1 receptor type A (Ednra) expression and incr

262 nes controlling vascular tone [endothelin-1, endothelin-1 receptor type A, and endothelial nitric oxi

263 physiologically important thromboxane A2 and endothelin-1 receptors.

264 with elevated vasoconstrictor signalling via endothelin-1, reduces the local vasodilatory response to

265 on vascular cells promoted interleukin-6 and endothelin-1 release.

266 activated gene networks involved in calcium, endothelin-1, renin-angiotensin, and cardiac beta-adrene

267 ystem (leads to activation of TGF-beta), and endothelin-1 secretion by macrophages in mediating tissu

268 Of these, the vasoconstrictive factor endothelin-1 serves as an integral point of communicatio

269 e C signaling, glutamate receptor signaling, endothelin 1 signaling, and cardiac hypertrophy signalin

270 Although the autocrine/paracrine nature of endothelin-1 signaling has been extensively studied, its

271 in-1 on podocytes has been shown in vivo and endothelin-1 signaling in podocytes has not been investi

272 Our data suggest that in diabetes, endothelin-1 signaling, as occurs in endothelial activat

273 resence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback loop.

274 Endothelin-1 stimulated the production of MMP1, MMP8, an

275 eNOS-activating region of ET(B) to decrease endothelin-1-stimulated eNOS activity.

276 +) transients and arrhythmias in response to endothelin-1 stimulation.

277 s of Src, Shc, and ERK, as well as increased endothelin-1 synthesis.

278 ects, but not in vascular dementia, in which endothelin 1 tended to be elevated, perhaps reflecting a

279 ased pressor responses to angiotensin II and endothelin-1; these effects are prevented by treatment w

280 These pathways were activated by endothelin-1 through the ETB receptor; inhibiting recept

281 l vein inhibits contractile force induced by endothelin-1 to a greater extent than the predominantly

282 ng enzyme-1 mRNA; or blocking the binding of endothelin-1 to the endothelin-A (ET(A)) receptor with e

283 pro-B-type natriuretic peptide, aldosterone, endothelin-1, troponin I, and C-telopeptide for type I c

284 ecipients the impact of Abs directed against endothelin-1 type A (ET(A)R) and angiotensin II type 1 r

285 n levels of the cannabinoid type 1 receptor, endothelin-1 type A receptor (ET(A) R), activator protei

286 anti-angiotensin II type-1 receptor and anti-endothelin-1 type A receptor autoantibodies are associat

287 tatus for angiotensin II type-1 receptor and endothelin-1 type A receptor autoantibodies pre-LT, and

288 s elicited by phenylephrine, angiotensin II, endothelin-1, U46619, and K(+)-induced membrane depolari

289 n enhances epidermal expression of TRPV4 and endothelin-1, underscoring the potential of keratinocyte

290 r analysis of the Bristol cohort showed that endothelin 1 was reduced in the white matter in Alzheime

291 The extracellular concentration of endothelin-1 was increased following GLO1-knockdown, whe

292 Moreover, Ca(2+) release stimulated by endothelin-1 was inhibited by Ned-19, ryanodine, or xest

293 Endothelin-1 was measured at baseline and 12 weeks.

294 amma inducible protein 10 (IP10; CXCL10) and endothelin 1 were raised and strongly correlated togethe

295 unction and the vasoconstrictive response to endothelin-1 were also observed using a liver perfusion

296 No clear associations with TNF or endothelin-1 were observed.

297 en-binding activity, soluble E-selectin, and endothelin-1) were significantly increased during HAE at

298 ce has been associated with raised levels of endothelin-1, which are common both before and after Fon

299 f humoral factors such as angiotensin II and endothelin-1, which in turn promote cardiac hypertrophy

300 es was increased expression and secretion of endothelin-1, which is also a known pruritogen.